Addex Therapeutics Ltd
Addex Therapeutics Ltd
Your view on ADXN
Overview
What the company does, where it operates, and who runs it.
About Addex Therapeutics Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Mark Dyer
- Headquarters
- Chemin des Mines, 9, Geneva, CH
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Mark Dyer
- Headquarters
- Chemin des Mines, 9, Geneva, CH
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors.
Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association.
The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Addex Therapeutics Ltd from FRC's valuation model, read against the market price. ADXN last traded at $2.83; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Addex Therapeutics Ltd. Starting points for Addex Therapeutics Ltd: EPS -$4.73, beta 2.02 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Addex Therapeutics Ltd. Addex Therapeutics Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Addex Therapeutics Ltd. Trailing twelve-month EPS for Addex Therapeutics Ltd stands at -$4.73. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$30.00
Median
$30.00
High
$30.00
Average target
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrMar 2022 | Next QtrJun 2022 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -CHF 9.56 | -CHF 2.59 | -CHF 4.74 | -CHF 3.24 |
| Low estimate | -CHF 9.56 | -CHF 2.59 | -CHF 4.74 | -CHF 3.24 |
| High estimate | -CHF 9.56 | -CHF 2.59 | -CHF 4.74 | -CHF 3.24 |
| No. of analysts | 1 | 1 | 2 | 1 |
| Year-ago EPS | — | — | -CHF 6.88 | — |
| Growth | — | — | +31.1% | — |
Revenue Estimate
| Revenue | Current QtrMar 2022 | Next QtrJun 2022 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | CHF 467918.00 | CHF 508134.00 | CHF 1.42M | CHF 6.13M |
| Low estimate | CHF 467918.00 | CHF 508134.00 | CHF 1.42M | CHF 6.13M |
| High estimate | CHF 467918.00 | CHF 508134.00 | CHF 1.42M | CHF 6.13M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | — | — | CHF 29972.00 | — |
| Growth | — | — | +4629.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Addex Therapeutics Ltd. Addex Therapeutics Ltd has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Addex Therapeutics Ltd valued side by side against its closest peers. Addex Therapeutics Ltd is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Addex Therapeutics Ltd executives and directors. Shares of Addex Therapeutics Ltd have traded between $6.51 and $12.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Addex Therapeutics Ltd. Coverage tracks Addex Therapeutics Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Addex Therapeutics Ltd.